New Malaria Vaccine Launched in Africa Promises Major Impact

Oxford-developed R21 vaccine aims to significantly reduce malaria deaths with affordable, effective doses.

Ivory Coast begins administering the R21 vaccine to children under two, with plans for wider African rollout.
The vaccine, developed by the University of Oxford and the Serum Institute of India, meets WHO's 75% efficacy target.
R21's low cost of under $4 per dose makes it accessible for low-income countries.
Health experts anticipate the vaccine will save hundreds of thousands of lives and contribute to malaria eradication efforts.
Gavi supports the introduction of malaria vaccines in 15 African countries this year, aiming to protect millions of children.